Omega Therapeutics, Inc. Common Stock
OMGA
OMGA was delisted on the 24th of February, 2025.
54 hedge funds and large institutions have $59M invested in Omega Therapeutics, Inc. Common Stock in 2024 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 15 reducing their positions, and 20 closing their positions.
200% more call options, than puts
Call options by funds: $33K | Put options by funds: $11K
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
21% less funds holding
Funds holding: 68 → 54 (-14)
44% less capital invested
Capital invested by funds: $105M → $59M (-$45.7M)
53% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 15
70% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$551K |
| 2 |
GAA
Green Alpha Advisors
Niwot,
Colorado
|
+$99.6K |
| 3 |
Pathstone Holdings
Englewood,
New Jersey
|
+$64.9K |
| 4 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
+$33.9K |
| 5 |
FIM
Freedom Investment Management
Hartford,
Connecticut
|
+$20K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$2.74M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$1.64M |
| 3 |
Jane Street
New York
|
-$442K |
| 4 |
Goldman Sachs
New York
|
-$394K |
| 5 |
Millennium Management
New York
|
-$348K |
OMGA Hedge Fund Activity: Q3 2024 in Review
54 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Omega Therapeutics, Inc. Common Stock (OMGA) for Q3 2024, worth a combined $59M — down 44% from $105M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of OMGA and 6 opened new positions — a net loss of 14 holders — while 15 trimmed existing stakes and 7 added.
The largest buyer was Renaissance Technologies, adding an estimated $551K. The largest seller was Artal Group, exiting entirely with an estimated $2.74M sold.
- 54 institutional investors held Omega Therapeutics, Inc. Common Stock (OMGA) as of Q3 2024, down from 68 in Q2 2024.
- Funds reported $59M of Omega Therapeutics, Inc. Common Stock stock for Q3 2024, down 44% quarter-over-quarter.
- 6 funds opened new Omega Therapeutics, Inc. Common Stock positions in Q3 2024 and 20 closed out, a net change of -14 holders.
- The largest Omega Therapeutics, Inc. Common Stock buyer in Q3 2024 was Renaissance Technologies, an estimated $551K added.
- The largest Omega Therapeutics, Inc. Common Stock seller in Q3 2024 was Artal Group, an estimated $2.74M sold.
Based on aggregated 13F filings for Q3 2024.